Novel Piezoelectric Amino-acid Ultrasound Transducer to Deliver Drugs Through the Blood Brain Barrier
Project Number5R01NS131310-02
Contact PI/Project LeaderNGUYEN, THANH
Awardee OrganizationUNIVERSITY OF CONNECTICUT STORRS
Description
Abstract Text
Abstract
Neurodegenerative diseases and brain cancers are challenging to treat due to the presence of blood brain barrier
(BBB), which is formed by tight junctions between endothelial cells in the microvasculature of the brain and
prevents most of the therapeutics from access to the brain tissues. Among several reported approaches,
ultrasound (US) has been demonstrated to be the most effective and safe method to facilitate the BBB opening.
External US is however limited in efficacy to small animals whose skull bone is thin. In the case of humans, the
thick skull bone absorbs more than 90% of US energy, requiring large and bulky arrays of external US
transducers, which often consumes several hours of stimulation and requires tedious MRI monitoring during the
sonication. Moreover, this extensive process is only useful for a single-time stimulation while research has shown
the opening of BBB requires repetitive application of US. Implanted US transducers have thus emerged as an
excellent alternative. Unfortunately, commercial US transducers rely on conventional piezoelectric materials,
which contain toxic elements such as Lead in PZT (Lead Zirconate Titanate) and are non-degradable, therefore
requiring invasive brain-surgery for removal. To overcome these problems, the PI’s group has recently developed
a new biodegradable piezoelectric transducer, based on Poly-L-Lactide (PLLA). PLLA however has a modest
piezoelectric constant and thus cannot generate a powerful US to open the BBB deep inside the brain tissue.
Glycine, a biodegradable and safe amino acid, has been found to possess an extremely high piezoelectric
constant, even comparable to that of piezoelectric ceramics like PZT. Unfortunately, glycine crystals are brittle
and difficult-to-handle, rendering the material challenging to be used for high performance piezoelectric US
transducer. Here, we propose a new strategy for material processing and device fabrication to (1) manufacture
a biodegradable, flexible, easy-to-use, and highly piezoelectric nanofiber film of glycine crystals embedded inside
a polycaprolactone (PCL) polymeric matrix and (2) employ this flexible glycine/polymer nanofibers to create a
powerful US transducer which is implanted into the brain to facilitate drug-delivery through the blood-brain barrier
(BBB) for the treatment of brain cancers. Our major hypothesis is that; the glycine-based ultrasound transducer
will be able to provide a sufficient acoustic wave which can facilitate a safe and transient opening of BBB for the
diffusion of anti-cancer drugs through the BBB to treat brain cancers. To demonstrate the hypothesis, we design
the project with three specific aims. Aim 1 is to assess the piezoelectric performance, characterize the functional
lifetimes, and evaluate acoustic field from the glycine/PCL transducer in vitro. Aim 2 is to asses safety (local and
systemic toxicity) of the implanted transducer and the applied US in a large animal model. Aim 3 is to assess
anti-tumor efficacy of the treatment using the implanted transducer + anti-cancer drugs in vivo.
Public Health Relevance Statement
Narrative
Neurodegenerative diseases and brain cancers are difficult to treat due to the presence of blood brain barrier
(BBB), which prevents most of therapeutic drugs from penetrating the tight junctions of endothelial cells in the
brain microvasculature and accessing the brain tissues. Ultrasound (US) has been shown to be the most effective
and safe method to induce the BBB opening, facilitating the drug delivery into the brain tissue. Here, we propose
a novel biodegradable US transducer based on biodegradable, flexible and highly piezoelectric nanofiber film of
glycine crystals embedded inside a polycaprolactone (PCL) polymeric matrix to facilitate drug delivery through
the BBB for the treatment of brain cancers
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
614209054
UEI
WNTPS995QBM7
Project Start Date
15-February-2023
Project End Date
31-January-2028
Budget Start Date
01-February-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$481,838
Direct Costs
$374,322
Indirect Costs
$107,516
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$481,838
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS131310-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS131310-02
Patents
No Patents information available for 5R01NS131310-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS131310-02
Clinical Studies
No Clinical Studies information available for 5R01NS131310-02
News and More
Related News Releases
No news release information available for 5R01NS131310-02
History
No Historical information available for 5R01NS131310-02
Similar Projects
No Similar Projects information available for 5R01NS131310-02